)
CSL Seqirus
Pictured: CSL Seqirus employee in the lab in Massachusetts, USA
Securing Health for All of Us
Derived from the expression 'securing health for all of us', CSL Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic and we have been committed to protecting public health ever since.
At CSL Seqirus, we stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world. As a global vaccine leader, our vision is that through the power of innovation, we will advance science to enhance public health worldwide.
Areas of Focus
Influenza Vaccines
COVID-19 Vaccines
Pandemic Response
In-Licensing
Antivenoms and Q fever vaccine
Our Manufacturing Expertise
CSL Seqirus operates state-of-the-art manufacturing facilities on three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world.
Pictured: CSL Seqirus manufacturing employees in Holly Springs, NC, USA
Our Products
As a global vaccine leader, CSL Seqirus has one of the broadest influenza vaccine portfolios in the world.
*World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed October 2020)
^de Boer, P. et al, A systematic review of health economic consequences of quadrivalent influenza vaccination, Expert review of Pharmacoeconomics & Outcomes Research, Volume 17, 2017 - Issue 3, p249-265. https://www.tandfonline.com/doi/full/10.1080/14737167.2017.1343145 (Accessed October 2020)
1 World Health Organisation. Newsroom Feature. 8 Things to know about pandemic influenza. Available online: https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza (Accessed October 2020)